Thalidomide Effects in the Post-transplantation Setting in Patients with Multiple Myeloma

References

• Hallek, M., Bergsagel, P. and Anderson, K. (1998) "Multiple myeloma: Increasing evidence for a multistep transformation process", Blood 91, 3–21.
   PubMed Web of Science ®Google Scholar
• Kyle, R., Beard, C., O'Fallon, W. and Kurland, L. (1994) "Incidence of multiple myeloma in Olmsted county, Minnesota: 1978 through 1990, with a review of the trend since 1945", J. Clin. Oncol. 12, 1577–1583.
   PubMed Web of Science ®Google Scholar
• Sampson, F.C., Beard, S.M., Scott, F. and Vandenberghe, E. (2001) "Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma", Br. J. Haematol. 113, 1015–1019.
   PubMed Web of Science ®Google Scholar
• Sporn, J.R. and McIntyre, O.R. (1986) "Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results", Semin. Oncol. 13, 318–325.
   PubMed Web of Science ®Google Scholar
• Tsuchiya, J., Murakami, H., Kanoh, T., Kosaka, M., Sezaki, T., Mikuni, C., Kawato, M., Takagi, T., Togawa, A. and Isobe, T. (1994) "Ten-year survival and prognostic factors in multiple myeloma. Japan myeloma study group", Br. J. Haematol. 87, 832.
   PubMed Web of Science ®Google Scholar
• Child, J.A., Morgan, G.J., Davies, FE., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. and Selby, P.J. (2003) "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma", N. Engl. J. Med. 348, 1875–1883.
   PubMed Web of Science ®Google Scholar
• Harousseau, J.-L. and Attal, M. (2003) "High-dose therapy in multiple myeloma", Hematol. J. 4, 163–170.
   PubMedGoogle Scholar
• Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996) "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", N. Engl. J. Med. 335, 91–97.
   PubMed Web of Science ®Google Scholar
• Bergsagel, D.E., Cowan, D.H. and Hasselback, R. (1972) "Plasma cell myeloma: response of melphalan-resistant patients to high dose intermittent cyclosphosphamide", Can. Med. Assoc. J. 107, 851–855.
   PubMed Web of Science ®Google Scholar
• Southwest Oncology Group Study (1975) "Remission main-tenance therapy for multiple myeloma", Arch. Intern. Med. 135, 147–152.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Barlogie, B. and Tucker, S. (1990) "VAD-based regimens as primary treatment for multiple myeloma", Am. J. Hematol. 33, 86–89.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Smith, L. and Alexanian, R. (1984) "Effective treatment of advanced multiple myeloma refractory to alkylating agents", N. Engl. J. Med. 310, 1353–1356.
   PubMed Web of Science ®Google Scholar
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. and Barlogie, B. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. Engl. J. Med. 341, 1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V., Hayman, S., Fonseca, R., et al. (2000) "Thalidomide plus dexamethasone (Thal/Dex) and thalido-mide alone (Thal) as first line therapy for newly diagnosed myeloma (MM) (abstract)", Blood 96, 168a.
   Web of Science ®Google Scholar
• Weber, D.M., Rankin, K., Gavino, M., Delasalle, K. and Alexanian, R. (2000) "Thalidomide with dexamethasone for resistant multiple myeloma", Blood 96, 167a.
   Web of Science ®Google Scholar
• Barlogie, B., Tricot, G. and Anaissie, E. (2001) "Thalidomide in the management of multiple myeloma", Semin. Oncol. 28, 577–582.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V., Dispenzieri, A., Fonseca, R., et al. (2001) "Thalidomide for previously untreated indolent or smolder-ing multiple myeloma", Leukemia 15, 1274–1276.
   PubMed Web of Science ®Google Scholar
• Rajkumar S.V., Gertz MA., Dispenzieri A., Lacy M.Q., Fonseca R., Hayman S., Geyer S., Lust J.A., Kyle R.A., Greipp P.R., Witzig T.E. (2001) "Thalidomide therapy for previously untreated, smoldering, and relapse multiple myeloma (MM) (abstract)", Meeting Proceedings of ASCO, 299a.
   Google Scholar
• Alexanian, R., Bonnet, J., Gehan, E., Haut, A., Hewlett, J., Lane, M., Monto, R. and Wilson, H. (1972) "Combination chemotherapy for multiple myeloma", Cancer 30, 382–389.
   PubMed Web of Science ®Google Scholar
• Hus, M., Dmoszynska, A., Soroka-Wojtaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., Hellman, A., Wolska-Smolen, T., Skotnicki, A. and Manko, J. (2001) "Thalidomide treatment of resistant or relapsed multiple myeloma patients", Haematologica 86, 404–408.
   PubMed Web of Science ®Google Scholar
• Geitz, H., Handt, S. and Zwingenberger, K. (1996) "Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade", Immunopharmacology 31, 213–221.
   PubMed Web of Science ®Google Scholar
• Corral, L.G., Muller, G.W., Moreira, AL., Chen, Y., Wu, M., Stirling, D. and Kaplan, G. (1996) "Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity", Mol. Med. 2, 506–515.
   PubMed Web of Science ®Google Scholar
• Haslett, PA., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset", J. Exp. Med. 187, 1885–1892.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Bathos, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. and Tricot, G. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients", Blood 98, 492–494.
   PubMed Web of Science ®Google Scholar
• Kneller, A., Raanani, P., Avigdor, A., Levi, I., Berkowicz, M. and Ben-Bassat, I. (2000) "Therapy with thalidomide in refractory multiple myeloma patients—the revival of an old drug", Br. J. Haematol. 108, 391–393.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V. and Kyle, R.A. (2001) "Angiogenesis in multiple myeloma", Semin. Oncol. 28, 560–564.
   PubMed Web of Science ®Google Scholar
• Parman, T., Wiley, M. and Wells, P.G. (1999) "Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity", Nat. Med. 5, 582–585.
   PubMed Web of Science ®Google Scholar
• Vacca A., Ria R., Semeraro F., Merchionne E, Coluccia M., Boccarelli A., Scavelli C., Nico B., Gernone A., Battelli F., Tabilio A., Guidolin D., Petrucci M.T., Ribatti D., Dammacco F. (2003) "Endothelial cells in the bone marrow of multiple myeloma", Blood First Edition Paper, prepublished online July 10, 2003.
   Google Scholar
• Eleutherakis-Papaiakovou, V, Karali, M., Kokkonouzis, I., Tiliakos, I. and Dimopoulos, MA. (2003) "Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach", Leuk. Lymphoma 44, 937–948.
   PubMed Web of Science ®Google Scholar
• Sampaio, E.P., Sarno, EN., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis alpha production by stimulated human monocytes", J. Exp. Med. 173, 699–703.
   PubMed Web of Science ®Google Scholar
• Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padro, T., Kropff, M., Scheffold, C., Kroger, M., Mesters, R.M., Berdel, W.E. and Kienast, J. (2003) "Paracrine interactions of basic fibroblast growth factor and interleuldn-6 in multiple myeloma", Blood 101, 2775–2783.
   PubMed Web of Science ®Google Scholar
• Nefedova, Y, Landowski, T.H. and Dalton, W.S. (2003) "Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanism", Leukemia 17, 1175–1182.
   PubMed Web of Science ®Google Scholar
• Alexandrakis, M.G., Passam, F.H., Boula, A., Christophoridou, A., Aloizos, G., Roussou, P. and Kyriakou, D.S. (2003) "Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma", Ann. Hematol. 82, 19–23.
   PubMed Web of Science ®Google Scholar
• Drevs, J. (2003) "Soluble markers for the detection of hypoxia under antiangiogenic treatment", Anticancer Res. 23, 1159–1161.
   PubMed Web of Science ®Google Scholar
• Li, X., Liu, X., Wang, J., Wang, Z., Jiang, W., Reed, E., Zhang, Y., Liu, Y. and Li, Q.Q. (2003) "Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin resistant human lung carcinoma cells", Anticancer Res. 23, 2481–2487.
   PubMed Web of Science ®Google Scholar
• Vacca, A., Ribatti, D., Roccaro, AM., Frigeri, A. and Dammacco, F. (2001) "Bone marrow angiogenesis in patients with active multiple myeloma", Semin. Oncol. 28, 543–550.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V. and Kyle, R.A. (2001) "Thalidomide in the treatment of plasma cell malignancies", J. Clin. Oncol. 19, 3593–3595.
   PubMed Web of Science ®Google Scholar
• Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., Triolo, S., Gallo, E., Pileri, A. and Boccadoro, M. (2001) "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma", Haematologica 86, 399–403.
   PubMed Web of Science ®Google Scholar
• Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Gangini, D., Pileri, S.A., Baccarani, M., Tura, S. and Cavo, M. (2001) "Salvage therapy with thalidomide in mul-tiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation", Haematologica 86,409–413.
   PubMed Web of Science ®Google Scholar